Krystal Biotech Equity 2024

Krystal Biotech Aktienanalyse

What does Krystal Biotech do?

Krystal Biotech Inc was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. The company specializes in the development and commercialization of gene therapy products. It has several divisions, including dermatological and musculoskeletal diseases, as well as Ebenezer and X-Linked Retinoschisis. In the history of the company, there have been several milestones. In 2017, the company completed its first financing round, raising $8 million. In the same year, it became the first company to successfully treat a patient with its gene therapy for epidermolysis bullosa. This was a major breakthrough as this disease is otherwise difficult to treat. In 2018, the company went public on the Nasdaq, raising over $50 million. In 2019, Krystal Biotech began developing a gene therapy product for hereditary angioedema. The company's business model is primarily based on the discovery and development of gene therapy products targeting genetic defects. The goal is to treat diseases that are otherwise difficult or impossible to treat. Krystal Biotech emphasizes that it follows a patient-centric approach in the development of its gene therapy products. Another part of the business model is collaborating with partner companies and institutions to advance the development and commercialization of its products. Krystal Biotech Inc has several divisions. The first division focuses on dermatological diseases. Its gene therapy products are designed to treat epidermolysis bullosa and Netherton syndrome. Epidermolysis bullosa is a rare disease caused by a mutation in collagen and other proteins, leading to blistering and lesions on the skin. Netherton syndrome is a disease that can also cause skin rashes and allergic reactions. Krystal Biotech offers gene therapy products to reduce the symptoms of these diseases and improve patients' quality of life. Another division is musculoskeletal diseases. Krystal Biotech Inc has developed gene therapy products to treat patients with osteoarthritis and sickle cell anemia. Osteoarthritis is a painful condition caused by the breakdown of cartilage in the joint. The gene therapy products offered by Krystal Biotech are intended to promote the regeneration of cartilage cells and support joint preservation. Sickle cell anemia is an inherited disease that causes red blood cells to have an abnormal shape and can block blood vessels. Krystal Biotech's gene therapy products are intended to reduce the risk of painful crises caused by this condition. Another division of Krystal Biotech is Ebenezer and X-Linked Retinoschisis. This is an inherited condition that affects vision. Krystal Biotech has developed gene therapy products to treat this problem. Overall, Krystal Biotech Inc has conducted promising research projects. The company has core expertise in gene therapy and can apply its innovations to various medical fields. The gene therapy products offered by Krystal Biotech are intended to improve patients' lives and treat diseases that are otherwise difficult to cure. Krystal Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Krystal Biotech's Equity

Krystal Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Krystal Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Krystal Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Krystal Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Krystal Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Krystal Biotech stock

What is the equity of Krystal Biotech this year?

Krystal Biotech has equity of 778.64 M USD this year.

What was the equity of Krystal Biotech compared to the previous year?

The equity of Krystal Biotech has increased/decreased by 49.11% increased compared to the previous year.

What impact does a high equity have on investors of Krystal Biotech?

A high equity is advantageous for investors of Krystal Biotech as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Krystal Biotech?

A low equity can be a risk for investors of Krystal Biotech, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Krystal Biotech affect the company?

An increase in equity of Krystal Biotech can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Krystal Biotech affect the company?

A reduction in equity of Krystal Biotech can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Krystal Biotech?

Some factors that can affect the equity of Krystal Biotech include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Krystal Biotech so important for investors?

The equity of Krystal Biotech is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Krystal Biotech take to change the equity?

To change equity, Krystal Biotech can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Krystal Biotech pay?

Over the past 12 months, Krystal Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Krystal Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Krystal Biotech?

The current dividend yield of Krystal Biotech is .

When does Krystal Biotech pay dividends?

Krystal Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Krystal Biotech?

Krystal Biotech paid dividends every year for the past 0 years.

What is the dividend of Krystal Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Krystal Biotech located?

Krystal Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Krystal Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Krystal Biotech from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did Krystal Biotech pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of Krystal Biotech in the year 2023?

In the year 2023, Krystal Biotech distributed 0 USD as dividends.

In which currency does Krystal Biotech pay out the dividend?

The dividends of Krystal Biotech are distributed in USD.